摘要
目的:评价康莱特注射液联合FOLFOX4方案治疗晚期大肠癌的疗效及不良反应.方法:将40例符合入选标准的晚期大肠癌患者分为治疗组和对照组.对照组仅以FOLFOX4方案化疗,治疗组在化疗同时静脉滴注康莱特注射液.2个周期结束后评价疗效及不良反应.结果:治疗组和对照组有效率(CR+PR)分别为25.0%和20.0%(P>0.05),疾病控制率(CR+PR+SD)分别为80.0%和75.0%(P>0.05);治疗组和对照组中医证候评定的显效+有效率分别为85.0%和50.0%(P<0.05);治疗组治疗后Karnofsky评分及体质量改变较对照组升高(P<0.05);治疗组及对照组生活质量评分改变未见明显差异;两组T抑制、杀伤细胞(CD3+CD8+)治疗前后变化无统计学差异.治疗组的T淋巴细胞(CD3+)、T辅助、诱导细胞(CD3+CD4+)、NK细胞(CD16+CD56+)水平较治疗前提高,而对照组则下降,且两组相比有统计学意义(P<0.05).治疗组的白细胞减少发生率低于对照组(P<0.05),其余不良反应未见显著差异.结论:康莱特注射液联合FOLFOX4方案治疗晚期大肠癌能够有效改善患者体力状况,提高免疫功能,减轻化疗不良反应.
AIM： To evaluate the efficacy and toxicity of Kanglaite injection combined with FOLFOX4 regimen in the treatment of advanced colorectal cancer.METHODS： In total, 40 patients with advanced colorectal cancer were randomly divided into treatment group and control group. The control group was treated using the FOLFOX4 regimen, and the treatment group were treated using the FOLFOX4 regimen combined with intravenous infusion of Kanglaite injection. After two cycles of therapy, the efficacy and toxicity were evaluated.RESULTS： The objective response rate and dis- ease control rate were higher in the treatmentgroup than in the control group, but the differ- ences were not significant （25.0% vs 20.0%, P 〉 0.05; 85.0% vs 75.0%, P 〉 0.05）. The stable rate of TCM syndromes after chemotherapy was 85.0% for the treatment group and 50.0% for the control group （P 〈 0.05）. KPS score and body weight in- creased significantly in the treatment group after therapy （both P 〈 0.05）. QOL score did not dif- fer significantly between the two groups. After therapy, the numbers of T lymphocytes （CD3＋）, T-assisted, induced lymphocytes （CD3＋CD4＋） and NK cells （CD16＋CD56＋） increased in the treatment group, but decreased in the control group （all P 〈 0.05）. Leucopenia incidence in the treatment group was lower than that in the control group （P 〈 0.05）. The incidences of other adverse reactions showed no significant differ- ences between the two groups.CONCLUSION： Kanglaite injection combined with FOLFOX4 regimen can improve physical condition, enhance immune function, and reduce chemotherapy toxicity in the treatment of advanced colorectal cancer.
出处
《世界华人消化杂志》
CAS
北大核心
2012年第29期2851-2854,共4页
World Chinese Journal of Digestology
基金
江苏省卫生厅医学科技发展基金资助项目
No.P200921~~
关键词
康莱特
晚期大肠癌
免疫功能
Kanglaite
Advanced colorectal cancer
Immune function
